Amy Schumer Reveals She Was ‘Bedridden’ After Trying Ozempic
The comedian dabbled with the diabetic drug that’s become a popular weight-loss method three years ago.

Noam Galai/Getty Images for SiriusXM
Amy Schumer recalled feeling so nauseous and lethargic after trying Ozempic three years ago that she became basically “bedridden.” In an interview with Howard Stern Wednesday, Schumer explained that she has a specific gene, GDF 15, which makes her particularly prone to nausea. “So I tried Ozempic almost three years ago, and I was like bedridden,” Schumer shared. “I was vomiting. And then you have no energy.” Although Ozempic is a diabetic medication, it has popularly been used as a weight-loss drug in recent years. While Schumer noted that she “lost 30 pounds so quick” and “looked great” after taking Ozempic, she added, “I couldn’t lift my head off the pillow, so what’s the point?” “I tried it and I was vomiting and I’m in bed and my son’s like, ‘Can you play tag?’ I’m like, ‘I can’t.’ I was shriveling,” the comedian continued. Schumer has famously been open about weight-loss procedures she’s undergone, admitting to getting liposuction in 2022. In a 2023 interview with Andy Cohen, the Trainwreck star slammed celebrities for purposefully concealing how they’ve lost weight. “Everybody’s lying. Everybody’s like, ‘Smaller portions.’ Like shut the f *** up,” Schumer said at the time. “You are on Ozempic or one of those things or you got work done. Just stop.”
Register below to read this article for free or subscribe
to unlock unlimited access to The Daily Beast.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Already have an account? Sign In
Looks like you already have a subscription!
You're all set!
Thanks for subscribing.